Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management
Tóm tắt
Từ khóa
Tài liệu tham khảo
Vincent, 2009, International study of the prevalence and outcomes of infection in intensive care units, JAMA, 302, 2323, 10.1001/jama.2009.1754
Centers for Disease Control and Prevention (CDC) Antibiotic resistance threats in the United States 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
Perez, 2013, Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients, Cleve Clin J Med, 80, 225, 10.3949/ccjm.80a.12182
Snitkin, 2012, Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing, Sci Transl Med, 4, 148ra16, 10.1126/scitranslmed.3004129
Boucher, 2009, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin Infect Dis, 48, 1, 10.1086/595011
Sievert, 2013, Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010, Infect Control Hosp Epidemiol, 34, 1, 10.1086/668770
Pfeifer, 2010, Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens, Int J Med Microbiol, 300, 371, 10.1016/j.ijmm.2010.04.005
Prabaker, 2011, Trends in antimicrobial resistance in intensive care units in the United States, Curr Opin Crit Care, 17, 472, 10.1097/MCC.0b013e32834a4b03
Doi, 2013, Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States, Clin Infect Dis, 56, 641, 10.1093/cid/cis942
Kanj, 2011, Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa, Mayo Clin Proc, 86, 250, 10.4065/mcp.2010.0674
Tzouvelekis, 2012, Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions, Clin Microbiol Rev, 25, 682, 10.1128/CMR.05035-11
Poirel, 2010, Diversity, epidemiology, and genetics of class D beta-lactamases, Antimicrob Agents Chemother, 54, 24, 10.1128/AAC.01512-08
Poirel, 2012, OXA-48-like carbapenemases: the phantom menace, J Antimicrob Chemother, 67, 1597, 10.1093/jac/dks121
Centers for Disease Control and Prevention (CDC), 2011, Carbapenem-resistant Klebsiella pneumoniae associated with a long-term-care facility - West Virginia, 2009-2011, MMWR Morb Mortal Wkly Rep, 60, 1418
Zavascki, 2010, Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy, Expert Rev Anti Infect Ther, 8, 71, 10.1586/eri.09.108
Pogue, 2013, Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management, Expert Rev Anti Infect Ther, 11, 383, 10.1586/eri.13.14
Kallen, 2010, Current epidemiology of multidrug-resistant gram-negative bacilli in the United States, Infect Control Hosp Epidemiol, 31, S51, 10.1086/655996
Bradford, 2001, Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat, Clin Microbiol Rev, 14, 933, 10.1128/CMR.14.4.933-951.2001
Dhillon, 2012, ESBLs: a clear and present danger?, Crit Care Res Pract, 2012, 625170
Falagas, 2009, Extended-spectrum beta-lactamase-producing organisms, J Hosp Infect, 73, 345, 10.1016/j.jhin.2009.02.021
Hawser, 2013, Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010, Int J Antimicrob Agents, 41, 224, 10.1016/j.ijantimicag.2012.10.014
Babinchak, 2013, Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010, Diagn Microbiol Infect Dis, 76, 379, 10.1016/j.diagmicrobio.2013.02.031
Bouchillon, 2013, Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011, Clin Ther, 35, 872, 10.1016/j.clinthera.2013.03.022
Centers for Disease Control and Prevention (CDC), 2013, Vital signs: carbapenem-resistant Enterobacteriaceae, MMWR Morb Mortal Wkly Rep, 62, 165
Zilberberg, 2013, Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009, J Hosp Med, 8, 559, 10.1002/jhm.2080
Landman, 2007, Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY, J Antimicrob Chemother, 60, 78, 10.1093/jac/dkm129
Routsi, 2013, Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients, Intensive Care Med, 39, 1253, 10.1007/s00134-013-2914-z
Sheng, 2010, A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii, Int J Infect Dis, 14, e764, 10.1016/j.ijid.2010.02.2254
Tacconelli, 2002, Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology, Emerg Infect Dis, 8, 220, 10.3201/eid0802.010121
Dommeti, 2011, Patterns of ciprofloxacin-resistant gram-negative bacteria colonization in nursing home residents, Infect Control Hosp Epidemiol, 32, 177, 10.1086/657946
Pop-Vicas, 2009, Influx of multidrug-resistant, gram-negative bacteria in the hospital setting and the role of elderly patients with bacterial bloodstream infection, Infect Control Hosp Epidemiol, 30, 325, 10.1086/596608
Marchaim, 2012, The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities, Am J Infect Control, 40, 760, 10.1016/j.ajic.2011.09.011
Pop-Vicas, 2008, Multidrug-resistant gram-negative bacteria in a long-term care facility: prevalence and risk factors, J Am Geriatr Soc, 56, 1276, 10.1111/j.1532-5415.2008.01787.x
Denkinger, 2013, Increased multi-drug resistance among the elderly on admission to the hospital-a 12-year surveillance study, Arch Gerontol Geriatr, 56, 227, 10.1016/j.archger.2012.05.006
Maragakis, 2010, Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit, Crit Care Med, 38, S345, 10.1097/CCM.0b013e3181e6cbc5
Evans, 2007, Cost of gram-negative resistance, Crit Care Med, 35, 89, 10.1097/01.CCM.0000251496.61520.75
Mauldin, 2010, Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria, Antimicrob Agents Chemother, 54, 109, 10.1128/AAC.01041-09
Maragakis, 2008, Clinical and economic burden of antimicrobial resistance, Expert Rev Anti Infect Ther, 6, 751, 10.1586/14787210.6.5.751
Centers for Disease Control and Prevention (CDC), 2009, Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities, MMWR Morb Mortal Wkly Rep, 58, 256
Tacconelli, 2014, ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients, Clin Microbiol Infect, 20, 1, 10.1111/1469-0691.12427
Dellit, 2007, Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship, Clin Infect Dis, 44, 159, 10.1086/510393
Tamma, 2012, Combination therapy for treatment of infections with gram-negative bacteria, Clin Microbiol Rev, 25, 450, 10.1128/CMR.05041-11
Pogue, 2014, Automated alerts coupled with antimicrobial stewardship intervention lead to decreases in length of stay in patients with gram-negative bacteremia, Infect Control Hosp Epidemiol, 35, 132, 10.1086/674849
Pitout, 2008, Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern, Lancet Infect Dis, 8, 159, 10.1016/S1473-3099(08)70041-0
Vardakas, 2012, Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis, J Antimicrob Chemother, 67, 2793, 10.1093/jac/dks301
Nguyen, 2014, Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae, J Antimicrob Chemother, 69, 871, 10.1093/jac/dkt450
Lodise, 2007, Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy, Clin Infect Dis, 44, 357, 10.1086/510590
Bauer, 2013, Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections, Antimicrob Agents Chemother, 57, 2907, 10.1128/AAC.02365-12
Dubrovskaya, 2015, Risk factors for nephrotoxicity onset associated with polymyxin B therapy, J Antimicrob Chemother, 70, 1903, 10.1093/jac/dkv014
Temocin, 2015, Incidence and Risk Factors for Colistin-Associated Nephrotoxicity, Jpn J Infect Dis, 68, 318, 10.7883/yoken.JJID.2014.223
Duin, 2013, Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes, Diagn Microbiol Infect Dis, 75, 115, 10.1016/j.diagmicrobio.2012.11.009
Forest Pharmaceuticals Inc, 2015, Avycaz (ceftazidime/avibactam) package insert
Cubist Pharmaceuticals, 2014, Zerbaxa (ceftolozane/tazobactam) package insert
The Medicines Company, 2014, Minocin (minocycline) package insert
Wyeth Pharmaceuticals Inc, 2014, Tygacil (tigecycline) package insert
Hoffmann, 2007, Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects, Drug Metab Dispos, 35, 1543, 10.1124/dmd.107.015735
Curcio, 2008, Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective, J Clin Microbiol, 46, 1892, 10.1128/JCM.02494-07
Monarch Pharmaceuticals, 2006, Coly-Mycin (colistin) package insert
Dalfino, 2012, High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study, Clin Infect Dis, 54, 1720, 10.1093/cid/cis286
Forest Pharmaceuticals Inc, 2007, Monurol [package insert]
Schintler, 2009, High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection, J Antimicrob Chemother, 64, 574, 10.1093/jac/dkp230
Matzi, 2010, Extracellular concentrations of fosfomycin in lung tissue of septic patients, J Antimicrob Chemother, 65, 995, 10.1093/jac/dkq070
Bergan, 1990, Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity, Infection, 18, S65, 10.1007/BF01643430
Prins, 1994, Once-daily gentamicin versus once-daily netilmicin in patients with serious infections-a randomized clinical trial, J Antimicrob Chemother, 33, 823, 10.1093/jac/33.4.823
Moore, 1987, Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration, J Infect Dis, 155, 93, 10.1093/infdis/155.1.93
Begg, 1999, The therapeutic monitoring of antimicrobial agents, Br J Clin Pharmacol, 47, 23, 10.1046/j.1365-2125.1999.00850.x
Baxter Corp, 2012, Gentamine (gentamicin) package insert
Daikos, 2014, Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems, Antimicrob Agents Chemother, 58, 2322, 10.1128/AAC.02166-13
Tumbarello, 2012, Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy, Clin Infect Dis, 55, 943, 10.1093/cid/cis588
Michalopoulos, 2010, Treatment of Acinetobacter infections, Expert Opin Pharmacother, 11, 779, 10.1517/14656561003596350
Denys, 2013, Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), Ann Clin Microbiol Antimicrob, 12, 24, 10.1186/1476-0711-12-24
Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13
Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253
Zhanel, 2014, Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli, Drugs, 74, 31, 10.1007/s40265-013-0168-2
U.S. Food and Drug Administration FDA approves new antibacterial drug Zerbaxa [press release] 2014 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm
Farrell, 2013, Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012), Antimicrob Agents Chemother, 57, 6305, 10.1128/AAC.01802-13
Juan, 2010, Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains, Antimicrob Agents Chemother, 54, 846, 10.1128/AAC.00834-09
Titelman, 2011, In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae, Diagn Microbiol Infect Dis, 70, 137, 10.1016/j.diagmicrobio.2011.02.004
Vanscoy, 2013, Pharmacological basis of beta-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane, Antimicrob Agents Chemother, 57, 5924, 10.1128/AAC.00656-13
Craig, 2013, In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice, Antimicrob Agents Chemother, 57, 1577, 10.1128/AAC.01590-12
Solomkin, 2015, Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, Phase 3 Trial (ASPECT-cIAI), Clin Infect Dis, 60, 1462, 10.1093/cid/civ097
Wagenlehner, 2015, Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI), Lancet, 385, 1949, 10.1016/S0140-6736(14)62220-0
Chandorkar, 2012, Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects, J Antimicrob Chemother, 67, 2463, 10.1093/jac/dks246
Gelfand, 2015, Ceftolozane/tazobactam therapy of respiratory infections due to multi-drug resistant Pseudomonas aeruginosa, Clin Infect Dis, 61, 853, 10.1093/cid/civ411
U.S. Food and Drug Administration FDA approves new antibacterial drug Avycaz [press release] 2015 http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm435629.htm
Zhanel, 2013, Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination, Drugs, 73, 159, 10.1007/s40265-013-0013-7
Lahiri, 2013, Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases, Antimicrob Agents Chemother, 57, 2496, 10.1128/AAC.02247-12
Aktas, 2012, In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae, Int J Antimicrob Agents, 39, 86, 10.1016/j.ijantimicag.2011.09.012
Lucasti, 2013, Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind. Phase II trial, J Antimicrob Chemother, 68, 1183, 10.1093/jac/dks523
Vazquez, 2012, Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study, Curr Med Res Opin, 28, 1921, 10.1185/03007995.2012.748653
Cerexa Inc Ceftazidime-Avibactam for injection for treatment of complicated intra-abdominal infection (used in combination with metronidazole), complicated urinary tract infection including acute pyelonephritis, and limited use indication: aerobic gram-negative infections with limited treatment options 2014 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM425459.pdf